STADA Arzneimittel has announced the acquisition of Sweden-based Lobsor Pharmaceuticals, gaining the rights to its triple-combination therapy of levodopa, carbidopa, and entacapone, delivered via modern pump technology, as a treatment for patients with late-stage Parkinson’s disease. The triple-combo treatment has already been approved in most…
The investigational gene therapy AXO-Lenti-PD continues to be well-tolerated and to ease disease symptoms in people with Parkinson’s, new SUNRISE-PD trial data covering a second and higher dose patient group indicate. Parkinson’s disease is characterized by a gradual loss of the neurons in the brain that make dopamine, a neurotransmitter involved…
Oral Ongentys (opicapone) as a daily add-on treatment shortened overnight “off” periods and eased dyskinesia during “on” periods in people with Parkinson’s disease using levodopa, new analyses of Phase 3 clinical trial data show. Long-term use was also seen to lower patients’ average daily levodopa dose without worsening symptoms…
Kynmobi (apomorphine hydrochloride), a sublingual film to treat “off” episodes in people with Parkinson’s disease, is now available in the United States by prescription, its developer Sunovion announced. “People living with Parkinson’s disease can potentially spend hours each day navigating disruptions caused by off episodes, which may…
Caffeinated drinks like coffee may help to protect people from Parkinson’s disease caused by mutations in the LRRK2 gene, much as research suggests it does in preventing sporadic, or non-familial, forms of this disease, a study reported. The study, “Association of caffeine and related analytes with resistance to Parkinson’s disease among…
Ongentys (opicapone) can reduce the extent of “off” periods in people with Parkinson’s disease being treated with levodopa, new clinical trial data show. The data were presented at the American Neurological Association 2020 Virtual Meeting. Therapies that aim to increase levels of dopamine in the brain,…
Portuguese pharmaceutical company BIAL has announced the opening of a Parkinson’s disease research facility in Cambridge, Mass., as part of its expansion to the United States under the name BIAL Biotech. Simultaneously, BIAL has acquired the Parkinson’s research programs operated by Lysosomal Therapeutics (LTI), including its lead candidate,…
The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application for mesdopetam (IRL790), an experimental therapy for reducing levodopa-induced dyskinesia, or involuntary movements, in people with Parkinson’s disease. This move by the FDA will allow for the enrollment of U.S. patients in…
Parkinson’s disease can be characterized as two different subtypes: one that starts in the brain and one that starts in the gut, a recent study suggests. This knowledge may open the door for the development of more personalized therapies, which could be based on the particular disease pattern of…
Spinal cord stimulation can effectively decrease pain, and also may help alleviate motor symptoms, in people with Parkinson’s disease (PD), regardless of whether patients have previously undergone deep brain stimulation, a small study suggests. The study, “Single arm prospective multicenter case series on the use of…
Get regular updates to your inbox.
